全文获取类型
收费全文 | 223035篇 |
免费 | 29525篇 |
国内免费 | 7169篇 |
专业分类
耳鼻咽喉 | 1727篇 |
儿科学 | 2047篇 |
妇产科学 | 5234篇 |
基础医学 | 16528篇 |
口腔科学 | 2174篇 |
临床医学 | 18490篇 |
内科学 | 21918篇 |
皮肤病学 | 1413篇 |
神经病学 | 774篇 |
特种医学 | 7590篇 |
外国民族医学 | 253篇 |
外科学 | 30850篇 |
综合类 | 28714篇 |
现状与发展 | 38篇 |
一般理论 | 3篇 |
预防医学 | 11075篇 |
眼科学 | 122篇 |
药学 | 15564篇 |
139篇 | |
中国医学 | 5379篇 |
肿瘤学 | 89697篇 |
出版年
2024年 | 715篇 |
2023年 | 4636篇 |
2022年 | 9201篇 |
2021年 | 11915篇 |
2020年 | 11020篇 |
2019年 | 9902篇 |
2018年 | 9533篇 |
2017年 | 10058篇 |
2016年 | 10736篇 |
2015年 | 12404篇 |
2014年 | 18047篇 |
2013年 | 17667篇 |
2012年 | 14497篇 |
2011年 | 14886篇 |
2010年 | 10817篇 |
2009年 | 11085篇 |
2008年 | 11407篇 |
2007年 | 10606篇 |
2006年 | 9412篇 |
2005年 | 7761篇 |
2004年 | 6424篇 |
2003年 | 5372篇 |
2002年 | 4489篇 |
2001年 | 4120篇 |
2000年 | 3470篇 |
1999年 | 2925篇 |
1998年 | 2443篇 |
1997年 | 2158篇 |
1996年 | 1720篇 |
1995年 | 1672篇 |
1994年 | 1342篇 |
1993年 | 1032篇 |
1992年 | 907篇 |
1991年 | 819篇 |
1990年 | 620篇 |
1989年 | 553篇 |
1988年 | 477篇 |
1987年 | 417篇 |
1986年 | 313篇 |
1985年 | 413篇 |
1984年 | 350篇 |
1983年 | 225篇 |
1982年 | 236篇 |
1981年 | 220篇 |
1980年 | 202篇 |
1979年 | 129篇 |
1978年 | 104篇 |
1977年 | 79篇 |
1976年 | 65篇 |
1975年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
91.
92.
93.
目的:研究乳腺癌细胞中转录调节因子c-Myb的表达对肺转移的影响及其分子机制。方法:构建c-Myb高表达的4T1乳腺癌细胞株,种植小鼠构建乳腺癌动物模型,检测实验动物肺转移情况,通过荷瘤抑制试验检测肺转移抑制效果。提取组织进行荧光PCR检测相关炎症因子的表达。利用Medisapiens数据库的生物信息学资源,对c-Myb和Ccl2的表达与乳腺癌患者的预后进行分析。结果:高表达c-Myb的荷瘤小鼠肺部转移灶明显减少,其中炎症相关因子表达受限。由数据库分析得出,c-Myb高表达患者生存期得以延长。结论:乳腺癌中c-Myb的表达能够通过炎症因子Ccl2抑制肺转移从而延长患者生存期。 相似文献
94.
W. Do T. Elzerman R. de Bree A. Rosenberg T. Forouzanfar E.M. Van Cann 《International journal of oral and maxillofacial surgery》2021,50(5):591-597
The aim of this study was to analyse the effect of body mass index (BMI), both low and high values, on the perioperative complication rate in patients with oral squamous cell carcinoma (OSCC). The medical records of 259 patients operated between 2014 and 2017 for OSCC were reviewed. Univariate and multivariate analyses were performed. Sixty of the 259 patients developed 87 complications. Low or high BMI was not associated with the perioperative complication rate. A longer operating time and increased blood loss were associated with a higher perioperative complication rate and higher Clavien–Dindo grade. Low BMI, American Society of Anesthesiologists score 2 and 3, a longer operating time, and increased blood loss were associated with a longer hospital stay. Low BMI was associated with a longer hospital stay. Neither low nor high BMI was associated with the perioperative complication rate. A longer operating time and increased blood loss were associated with a higher perioperative complication rate and higher Clavien–Dindo grade. 相似文献
95.
96.
IntroductionThe prognosis of patients with Oral squamous cell carcinoma (OSCC) are directly related to the stage of development of the tumor at the time of diagnosis, but it is estimated an average delay in diagnosis of 2–5 months. New non-invasive techniques for the early diagnosis of OSCC are being developed, such as methodologies to detect spectral changes of tumor cells. We conducted a systematic review to analyze the potential use of autofluorescence and/or fluorescent probes for OSCC diagnosis.Material and MethodsFour databases (PubMed, Scopus, Embase and Web of Science) were used as research sources. Protocol was registered with PROSPERO. It was included studies that evaluated tissue autofluorescence and/or used fluorescent probes as a method of diagnosing and/or treatment of oral cancer in humans.ResultsForty-five studies were selected for this systematic review, of which 28 dealt only with autofluorescence, 18 on fluorescent probes and 1 evaluated both methods. The VELscope® was the most used device for autofluorescence, exhibiting sensitivity (33%–100%) and specificity (12%–88.6%). 5-Aminolevulinic acid (5-ALA) was the most used fluorescent probe, exhibiting high sensitivity (90%–100%) and specificity (51.3%–96%). Hypericin, rhodamine 6 G, rhodamine 610, porphyrin and γ-glutamyl hydroxymethyl rhodamine green have also been reported.ConclusionThus, the autofluorescence and fluorescent probes can provide an accurate diagnosis of oral cancer, assisting the dentist during daily clinical activity, but it is not yet possible to suggest that this method may replace histopathological examination. 相似文献
97.
《Clinical genitourinary cancer》2022,20(3):e217-e226
Background: Intraductal carcinoma and cribriform (IDC/C) tumor features are well-established prognosticators of biochemical recurrence (BCR), metastasis, and prostate cancer (PCa)-specific mortality. However, approximately 70% of PCa patients undergoing a radical prostatectomy are IDC/C negative, yet up-to 20% of these patients progress and experience BCR. Thus, tumor histopathologic characteristics such as IDC/C alone are limited in their ability to predict disease progression. Conversely, several nomograms such as Cancer of the Prostate Risk Assessment-Surgery (CAPRA-S) have been developed to aid in the prognostication of BCR, but not yet widely applied in clinical settings. Materials and methods: In this study, we assessed the combined prognostic utility of IDC/C, and CAPRA-S for BCR in 3 PCa patient cohorts. Results: CAPRA-S+IDC/C improved the predictive accuracy of BCR in all 3 cohorts (P < .001). Specifically, among IDC/C negative cases, CAPRA-S improved the prognostication of BCR in low-risk (Cohort 1; P < .001, Cohort 2; P < .001, Cohort 3; P = .003), intermediate (Cohort 1; P < .001, Cohort 2; P = .006, Cohort 3; P = .03) and high-risk (Cohort 1-3; P < .001) patients. Conversely, IDC/C improved the prognostication of BCR among CAPRA-S low-risk (Cohorts 1; P < .001 and Cohort 3; P = .003) patients. Conclusion: Our results suggest the investigation of histopathological IDC/C features in CAPRA-S low-risk patients and conversely, nomogram CAPRA-S among IDC/C negative patients improves the identification of patients likely to experience BCR, which would otherwise be missed through current assessment regimens. These patients can be offered more intensive monitoring and adjuvant therapies upfront to circumvent the development of recurrent cancer or overtreatment at the time of surgery. 相似文献
98.
99.
Rian M. Hasson Kayla A. Fay Joseph D. Phillips Timothy M. Millington David J. Finley 《American journal of surgery》2021,221(4):725-730
BackgroundRural populations face many health disadvantages compared to urban areas. There is a critical need to better understand the current lung cancer screening landscape in these communities to identify targeted areas to improve the impact of this proven tool.MethodsData from the County Health Rankings of New Hampshire and Vermont was reviewed for population density, distribution of adult smokers, and level of education compared to the distribution of Lung Cancer Screening Facilities throughout these two states.ResultsScreening programs in southern counties of Vermont with lower levels of education have decreased access. In New Hampshire, there are no programs within 30 miles of the areas with the largest distribution of smokers, and decreased access in some areas with the lowest levels of education.ConclusionsImproving equitable access to high-quality screening services in rural regions and the creation of targeted interventions to address decreased access in areas of high tobacco use and low education is vital to decreasing the incidence of latestage presentations of lung cancer within these populations. 相似文献
100.
《Clinical oncology (Royal College of Radiologists (Great Britain))》2022,34(7):472-479
AimsTreatment decisions for older patients with breast cancer are complex and evidence is largely extrapolated from younger populations. Frailty and comorbidity need to be considered. We studied the baseline characteristics and treatment decisions in older patients in Christchurch with breast cancer and assessed survival outcomes and prognostic/discriminatory performance of several tools.Materials and methodsWe searched the Canterbury Breast Cancer Registry and identified patients aged 70 years or older at diagnosis with invasive, non-metastatic breast cancer between 1 June 2009 and 30 June 2015. We retrieved demographics, treatment and outcome information. Overall survival and breast cancer-specific survival were estimated. Tools analysing performance status and comorbidity were assessed for their prognostic and discriminatory power.ResultsIn total, 440 patients were identified. Primary surgery was carried out for 362 patients (82.3%): breast-conserving surgery in 114 (of whom 88.6% received radiation therapy); mastectomy in 248 (of whom 24.6% received radiation). Hormone therapy was given for 265 (71.1%) patients with oestrogen receptor-positive cancers. Two hundred and seventy-four (62.3%) patients received full standard treatment, which was associated with significantly improved 5-year survival and 5-year breast cancer-specific survival. The median estimated overall survival was 8.2 years (95% confidence interval 7.3–9.1 years). Of those who died, 71.3% of deaths were due to causes other than breast cancer or unknown causes. The comorbidity-adjusted life expectancy (CALE) showed partial prognostic accuracy. CALE, Charlson and Eastern Cooperative Oncology Group tools all showed discriminatory value.ConclusionIn this population-based series of older patients with breast cancer, showing high levels of primary and adjuvant treatment, patients were more likely to die of causes other than breast cancer. Performance status and comorbidity tools showed prognostic and discriminatory potential in this population supporting their use in treatment decision making. CALE showed the most potential to improve treatment decisions but requires validation in this population to improve prognostic accuracy. 相似文献